The Central Drugs Standard Control Organisation is upgrading its regulatory system with AI to speed up drug approvals. By hiring 1,500 internal scientific experts, the regulator aims to reduce delays, potentially benefiting domestic pharmaceutical and contract research companies looking for faster project execution.
The Central Drugs Standard Control Organisation (CDSCO) is moving toward a digital regulatory framework, signaling a significant shift in how drugs and medical products are approved in India. The regulator is currently evaluating bids from 12 technology firms to implement an artificial intelligence-based system designed to automate processes and reduce manual interventions. By integrating AI and data analytics, the agency expects to identify areas that need deeper scrutiny while speeding up standard approval paths for compliant applications.
Alongside the technological upgrade, the regulator is addressing one of the industry's longest-standing bottlenecks: personnel shortages. The government has approved the creation of an internal scientific cadre of 1,500 positions. Currently, drug reviews often rely on external subject expert committees, which can lead to scheduling conflicts and process delays. By transitioning these reviews to a dedicated in-house team, the CDSCO aims to create a more consistent and predictable timeline for pharmaceutical manufacturers and contract research organizations (CROs).
The regulatory landscape is also evolving to encourage more clinical trial activity. Domestic clinical trials are projected to reach 160 this year, up from approximately 130 previously. To facilitate this, the CDSCO has introduced digital submission processes for various research activities, removing the need for manual paperwork. The regulator is also refining guidelines for similar biologics and reviewing policies that could allow for first-in-human studies on international assets to be conducted within India. These changes are part of an effort to align local regulatory practices with global benchmarks and make the domestic market more attractive for multinational pharmaceutical investments.
For investors and companies in the pharmaceutical sector, these changes are critical to watch. Regulatory delays have historically been a drag on the profitability and growth timelines for many R&D-focused companies and CROs. If the transition to AI and the new staffing model leads to faster approval cycles, it could allow firms to bring products to market or conclude research projects more efficiently. However, the implementation of such large-scale digital and organizational changes carries inherent risks. The transition phase may introduce initial friction, and the effectiveness of the new system will depend on how smoothly the AI integrates with existing processes and how quickly the new scientific team is recruited and trained. Investors will likely monitor the rollout next month and the subsequent impact on the average time taken for drug approvals and trial registrations.